Dr. med explained. David Szynkarski of the Mann Eye Institute based in Houston, Texas. “The Mann Eye Institute has set itself the task of making groundbreaking advances in ophthalmology. The LACRIFILL Canalicular Gel allows us to provide better...
remains. The NeuroPulse pilot provides a clinical signal that the next frontier in AF treatment may lie outside the heart itself, with non-invasive, wearable neuromodulation opening the possibility of an entirely new treatment category for EPs and...
Founded in 1969, PHC Corporation is a Japanese operating company of PHC Holdings Corporation (Securities Code 6523 TSE Prime), a global healthcare company from Japan. We develop, manufacture, and sell research and medical support equipment that are...
demand for flexible, non-dilutive financing solutions across the life sciences ecosystem. Excedr has established itself as a trusted partner to both emerging biotech companies and established industry players, supported by long-standing...
unit economics, Nick and Josh have taken a fundamentally different approach: automating the physical fulfillment layer itself,” said Will Coffield, Partner at Riot Ventures. “Queue is exactly the kind of company Riot backs early. It has exceptional...
Ascensia Diabetes Care, a global diabetes care company and subsidiary of PHC Holdings Corporation (TSE 6523), announced the launch of CONTOUR®COMFORT pen needles, further strengthening its CONTOUR® portfolio with a solution that improves the...
specialized capabilities in research, development, manufacturing, and regulatory affairs, the company has established itself as a strategic national institution, contributing to the growth and productivity of the agricultural sector, the protection...
services, supporting pharmaceutical, biotech and medical device companies worldwide. "ProductLife Group has established itself as a trusted partner to the life sciences industry. I am excited to join the organization and work alongside its teams to...
(MedRxiv). Because NAD+ is not bioavailable and cannot effectively raise NAD+ levels in the body, supplementing with NAD+ itself is not recommended. Furthermore, oral or intravenous NAD+ supplementation has not been well studied in humans, and its...
engineered, potential first-in-class B7-H3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed by Daiichi Sankyo and Merck (NYSE: MRK), known as MSD outside of the United States and...
him to lead our commercial team and support our growth.” During his tenure at Harro Höfliger, the company established itself as a premium equipment supplier to the biopharmaceutical industry. Under his leadership, the business expanded beyond...
CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, today announced the successful treatment of the first sickle...
rigorous in-process controls and regulatory alignment at every step." With this launch, ProBio continues to position itself as a strategic partner for gene therapy innovators—offering agile, phase-appropriate manufacturing solutions that evolve...
emphasizes: "Constant ear noise caused by tinnitus can be even more stressful for many patients than the hearing loss itself. With AC102, we hope to eventually have an effective remedy for both conditions. This would be a great relief for patients...
Craft Telemedicine is actively seeking partnerships with high-quality compounding pharmacies nationwide, positioning itself as the preferred telemedicine platform for pharmacies seeking to grow their patient base without compromising their values...
pain, diarrhea, and nausea, which were not observed with Niagen IV. A common misconception is that the NAD+ molecule itself is bioavailable and that consumers can experience elevated NAD+ levels by taking NAD+ itself orally or intravenously. As a...
is committed to providing innovative healthcare solutions and driving rapid growth in the industry. It has established itself as a key player in the Latin American pharmaceutical market through its robust distribution network and strategic...
and services in more than 125 countries. About Cyfuse Biomedical K.K.: Cyfuse Biomedical K.K. (Securities Code: 4892, TSE Growth) is a regenerative medicine startup founded in 2010. Using its proprietary bio 3D printing technology, which creates...
and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.
MASH will be combination therapy. The company further believes that Aramchol' s unique mechanism of action differentiates itself from others in the competitive landscape, potentially positioning it to work as a potent anti-fibrotic compound...
